Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $297.16 billion. The enterprise value is $323.66 billion.
Market Cap | 297.16B |
Enterprise Value | 323.66B |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024, before market open.
Earnings Date | Oct 24, 2024 |
Ex-Dividend Date | Sep 16, 2024 |
Share Statistics
Merck & Co. has 2.53 billion shares outstanding. The number of shares has increased by 0.28% in one year.
Shares Outstanding | 2.53B |
Shares Change (YoY) | +0.28% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.07% |
Owned by Institutions (%) | 78.62% |
Float | 2.53B |
Valuation Ratios
The trailing PE ratio is 21.77 and the forward PE ratio is 13.73. Merck & Co.'s PEG ratio is 0.33.
PE Ratio | 21.77 |
Forward PE | 13.73 |
PS Ratio | 4.76 |
Forward PS | 4.35 |
PB Ratio | 6.82 |
P/FCF Ratio | 22.60 |
PEG Ratio | 0.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.70, with an EV/FCF ratio of 24.62.
EV / Earnings | 23.56 |
EV / Sales | 5.18 |
EV / EBITDA | 13.70 |
EV / EBIT | 16.37 |
EV / FCF | 24.62 |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.87.
Current Ratio | 1.47 |
Quick Ratio | 0.93 |
Debt / Equity | 0.87 |
Debt / EBITDA | 1.58 |
Debt / FCF | 2.87 |
Interest Coverage | 15.94 |
Financial Efficiency
Return on equity (ROE) is 33.38% and return on invested capital (ROIC) is 15.73%.
Return on Equity (ROE) | 33.38% |
Return on Assets (ROA) | 11.38% |
Return on Capital (ROIC) | 15.73% |
Revenue Per Employee | $867,778 |
Profits Per Employee | $190,778 |
Employee Count | 72,000 |
Asset Turnover | 0.58 |
Inventory Turnover | 2.44 |
Taxes
In the past 12 months, Merck & Co. has paid $1.50 billion in taxes.
Income Tax | 1.50B |
Effective Tax Rate | 9.82% |
Stock Price Statistics
The stock price has increased by +9.19% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
Beta (5Y) | 0.40 |
52-Week Price Change | +9.19% |
50-Day Moving Average | 118.27 |
200-Day Moving Average | 122.26 |
Relative Strength Index (RSI) | 50.54 |
Average Volume (20 Days) | 8,638,272 |
Short Selling Information
The latest short interest is 25.91 million, so 1.02% of the outstanding shares have been sold short.
Short Interest | 25.91M |
Short Previous Month | 26.72M |
Short % of Shares Out | 1.02% |
Short % of Float | 1.02% |
Short Ratio (days to cover) | 2.47 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $62.48 billion and earned $13.74 billion in profits. Earnings per share was $5.39.
Revenue | 62.48B |
Gross Profit | 47.35B |
Operating Income | 19.77B |
Pretax Income | 15.23B |
Net Income | 13.74B |
EBITDA | 23.63B |
EBIT | 19.77B |
Earnings Per Share (EPS) | $5.39 |
Balance Sheet
The company has $11.35 billion in cash and $37.79 billion in debt, giving a net cash position of -$26.43 billion or -$10.43 per share.
Cash & Cash Equivalents | 11.35B |
Total Debt | 37.79B |
Net Cash | -26.43B |
Net Cash Per Share | -$10.43 |
Equity (Book Value) | 43.65B |
Book Value Per Share | 17.19 |
Working Capital | 12.15B |
Cash Flow
In the last 12 months, operating cash flow was $16.69 billion and capital expenditures -$3.54 billion, giving a free cash flow of $13.15 billion.
Operating Cash Flow | 16.69B |
Capital Expenditures | -3.54B |
Free Cash Flow | 13.15B |
FCF Per Share | $5.19 |
Margins
Gross margin is 75.79%, with operating and profit margins of 31.64% and 21.98%.
Gross Margin | 75.79% |
Operating Margin | 31.64% |
Pretax Margin | 24.41% |
Profit Margin | 21.98% |
EBITDA Margin | 37.82% |
EBIT Margin | 31.64% |
FCF Margin | 21.04% |
Dividends & Yields
This stock pays an annual dividend of $3.08, which amounts to a dividend yield of 2.63%.
Dividend Per Share | $3.08 |
Dividend Yield | 2.63% |
Dividend Growth (YoY) | 5.48% |
Years of Dividend Growth | 14 |
Payout Ratio | 57.18% |
Buyback Yield | -0.28% |
Shareholder Yield | 2.35% |
Earnings Yield | 4.62% |
FCF Yield | 4.42% |
Analyst Forecast
The average price target for Merck & Co. is $134.58, which is 14.80% higher than the current price. The consensus rating is "Buy".
Price Target | $134.58 |
Price Target Difference | 14.80% |
Analyst Consensus | Buy |
Analyst Count | 12 |
Revenue Growth Forecast (5Y) | 5.98% |
EPS Growth Forecast (5Y) | 146.04% |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
Last Split Date | Feb 17, 1999 |
Split Type | Forward |
Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 4.57 and a Piotroski F-Score of 7.
Altman Z-Score | 4.57 |
Piotroski F-Score | 7 |